R&D channel feed – Endpoints News

R&D channel feed

As Eli Lilly suffers a sharp setback on revenue projections, the oncology group quietly executes 2 of its top mid-stage drugs

7 years ago

EU universities are miserably lax at reporting clinical trial results, analysis suggests

7 years ago

FDA tags Bayer's prostate cancer drug for priority review as drugmaker gears up against rivals

7 years ago

Keytruda PhIII failure in gastric cancer blights Merck's quest for frontline dominance

7 years ago

Celebrating sustained sales growth, AstraZeneca quietly executes some aging mid-stage drug projects

7 years ago

Gilead's selonsertib fails PhIII in less sick NASH patients — to no one's surprise

7 years ago

Another one of Bristol-Myers' PD-1/CTLA-4 combo studies bites the dust

7 years ago

Incensed by China CRISPR scandal, US consortium amplify global call to suspend human embryo editing

7 years ago

What does the past generation of failure in Alzheimer’s R&D look like in one slide?

7 years ago

An 'obligation to rebound': Biogen backs further away from aducanumab as R&D team hunts down late-stage M&A opportunities

7 years ago

Anxious to fill Humira-sized revenue hole ahead of US patent cliff, AbbVie hits the ground running with FDA approval for Skyrizi

7 years ago

Teva’s migraine drug can’t stop another bad R&D headache as researchers scrap a failed PhIII program for Ajovy

7 years ago

GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind

7 years ago

The biotech era in late-stage drug R&D and marketing has arrived. And it looks like it’s here to stay

7 years ago

As safety looms larger in CAR-T research, study highlights how small tweaks can make it easier to use

7 years ago

Positive pivotal Lilly data set stage for Taltz approval in non-radiographic axial spondyloarthritis

7 years ago

As rivals wait in line, Merck's Keytruda scores early FDA nod for frontline patients with the most common form of kidney cancer

7 years ago

RIP tanezumab? Eli Lilly, Pfizer spotlight alarming safety data for NGF pain drug in PhIII

7 years ago

Two gene therapy approvals headline CBER’s FY 2018 report

7 years ago

GlaxoSmithKline R&D reorganization triggers layoffs at Stevenage -- and Upper Providence

7 years ago

Biotech startup grabs $27M launch round to pursue an R&D path blazed at Harvard and Boston Children’s

7 years ago

Fresh safety, tolerability data snapshot from early-stage study of Wave's DMD drug spooks investors

7 years ago

'Patients are not a company's resource': FDA cancer czar Richard Pazdur has a bone to pick with the top R&D execs in cancer

7 years ago

London listed PureTech Health joins forces with ninth big pharma partner — Boehringer Ingelheim

7 years ago

First page Previous page 247 248 249250251 252 253 Next page Last page